YU35398A - Upotreba inhibitora ugljenične anhidraze za tretiranje makularne edeme - Google Patents

Upotreba inhibitora ugljenične anhidraze za tretiranje makularne edeme

Info

Publication number
YU35398A
YU35398A YU35398A YU35398A YU35398A YU 35398 A YU35398 A YU 35398A YU 35398 A YU35398 A YU 35398A YU 35398 A YU35398 A YU 35398A YU 35398 A YU35398 A YU 35398A
Authority
YU
Yugoslavia
Prior art keywords
carbonic anhydrase
macular edema
anhydrase inhibitors
treating macular
treating
Prior art date
Application number
YU35398A
Other languages
English (en)
Other versions
YU49422B (sh
Inventor
William Eric Sponsel
Alon Harris
Original Assignee
Advanced Research And Technology Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605642.9A external-priority patent/GB9605642D0/en
Application filed by Advanced Research And Technology Institute filed Critical Advanced Research And Technology Institute
Publication of YU35398A publication Critical patent/YU35398A/sh
Publication of YU49422B publication Critical patent/YU49422B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Eye Examination Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Opisan je postupak za tretiranje i/ili prevenciju makularnog edema i makularne degeneracije izazvane sa starošću koji obuhvata topikalnu primenu inhibitora ugljenične anhidraze na oko.[There is disclosed a method for treating and/or preventing macular edema and age-related macular degeneration which comprises topical administration of carbonic anhydrase inhibitors to the eye.
YU35398A 1996-02-26 1997-02-25 Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću YU49422B (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1225096P 1996-02-26 1996-02-26
GBGB9605642.9A GB9605642D0 (en) 1996-03-18 1996-03-18 Treatment of macular edema

Publications (2)

Publication Number Publication Date
YU35398A true YU35398A (sh) 2001-12-26
YU49422B YU49422B (sh) 2006-01-16

Family

ID=26308946

Family Applications (1)

Application Number Title Priority Date Filing Date
YU35398A YU49422B (sh) 1996-02-26 1997-02-25 Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću

Country Status (26)

Country Link
EP (1) EP0954305B9 (sh)
JP (1) JP4392481B2 (sh)
KR (1) KR100471586B1 (sh)
CN (1) CN1225582A (sh)
AT (1) ATE239468T1 (sh)
AU (1) AU727565B2 (sh)
BG (1) BG64525B1 (sh)
BR (1) BR9707674A (sh)
CA (1) CA2247063C (sh)
CZ (1) CZ299509B6 (sh)
DE (1) DE69721824T2 (sh)
DK (1) DK0954305T3 (sh)
EA (1) EA001681B1 (sh)
EE (1) EE03804B1 (sh)
ES (1) ES2199348T4 (sh)
HU (1) HU227161B1 (sh)
IL (1) IL125912A0 (sh)
IS (1) IS2053B (sh)
MX (1) MXPA98006961A (sh)
NO (1) NO320043B1 (sh)
NZ (1) NZ331843A (sh)
PT (1) PT954305E (sh)
SK (1) SK284371B6 (sh)
TR (1) TR199801665T2 (sh)
WO (1) WO1997030704A2 (sh)
YU (1) YU49422B (sh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
EP1058546A4 (en) * 1998-03-06 2004-07-28 Univ Texas COMPILATIONS AND METHODS FOR THE TREATMENT OF MACULA DISEASES
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
JP2002520287A (ja) * 1998-07-10 2002-07-09 ザ・ユニバーシティ・オブ・シドニー 黄斑変性における血管新生の予防的治療
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20100063035A1 (en) 2006-12-15 2010-03-11 Nicox S.A. Carbonic anhydrase inhibitors derivatives
AR084194A1 (es) * 2010-12-09 2013-04-24 Fovea Pharmaceuticals Derivados de arilsulfonamida para la prevencion o el tratamiento de trastornos oftalmologicos especificos
JP2020504711A (ja) 2016-12-21 2020-02-13 バイオセリックス， インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
GB2223166B (en) * 1988-09-29 1992-03-18 American Cyanamid Co Stable ophthalmic preparations containing methazolamide
US5153192A (en) * 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors

Also Published As

Publication number Publication date
DE69721824T2 (de) 2004-03-11
NO983906D0 (no) 1998-08-25
HUP9902054A3 (en) 2001-07-30
BR9707674A (pt) 2000-01-04
NO983906L (no) 1998-10-19
IS4829A (is) 1998-08-20
EP0954305B1 (en) 2003-05-07
EA001681B1 (ru) 2001-06-25
WO1997030704A2 (en) 1997-08-28
KR19990087242A (ko) 1999-12-15
DE69721824D1 (de) 2003-06-12
ES2199348T3 (es) 2004-02-16
CZ299509B6 (cs) 2008-08-20
IL125912A0 (en) 1999-04-11
TR199801665T2 (xx) 1998-12-21
NO320043B1 (no) 2005-10-17
HUP9902054A1 (hu) 2000-03-28
KR100471586B1 (ko) 2005-07-11
ATE239468T1 (de) 2003-05-15
MXPA98006961A (es) 2004-11-19
BG64525B1 (bg) 2005-06-30
CA2247063A1 (en) 1997-08-28
ES2199348T4 (es) 2010-10-19
BG102797A (en) 1999-09-30
EP0954305A2 (en) 1999-11-10
AU1972197A (en) 1997-09-10
JP2000506833A (ja) 2000-06-06
PT954305E (pt) 2003-09-30
NZ331843A (en) 2000-09-29
WO1997030704A3 (en) 1997-09-25
EE9800263A (et) 1999-08-16
DK0954305T3 (da) 2003-08-25
EP0954305B9 (en) 2010-08-04
HU227161B1 (en) 2010-09-28
CZ269998A3 (cs) 2000-01-12
SK284371B6 (sk) 2005-02-04
YU49422B (sh) 2006-01-16
EA199800764A1 (ru) 1999-06-24
CA2247063C (en) 2004-01-06
AU727565B2 (en) 2000-12-14
SK115198A3 (en) 2000-01-18
JP4392481B2 (ja) 2010-01-06
EE03804B1 (et) 2002-08-15
CN1225582A (zh) 1999-08-11
IS2053B (is) 2005-10-14

Similar Documents

Publication Publication Date Title
MXPA98006961A (es) Tratamiento de edema macular.
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
AU3922193A (en) Liposome encapsulated taxol and a method of using the same
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
HU9301272D0 (en) Method for treating inflammations and wounds using plasminogene activator inhibitors
WO2000059487A3 (en) Flupirtine in the treatment of fibromyalgia and related conditions
MXPA99002296A (es) Metodo para tratar alopecia androgenica con inhibidores de reductasa 5-alfa.
AU2838101A (en) Use of melatonin for treating androgenetic and diffuse alopecia
UA66757C2 (en) Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration
AU2763299A (en) Treatment of brain edema using carbonic anhydrase enzyme inhibitor
WO1996036339A3 (en) Use of dihydrotestosterone compounds for treating male sexual dysfunction
IL126158A0 (en) Method for treating substance abuse
AU7340694A (en) Treatment of age-related macular degeneration
AU6929396A (en) Preperation for the prophylaxis and/or treatment of wool and hair loss
AU4057789A (en) Method for using protease inhibitors to treat and/or prevent pancreatitis
MD1296F1 (en) The Nicolau method of treatment of the lichen planus
UA13880A (uk) Спосіб профілактики післяопераційhих ускладhеhь
GB9605642D0 (en) Treatment of macular edema
GEP19971009B (en) Flupirtine in combination with antiparkinsonica against muscle bracing